VEGFA and renal cell carcinoma: The first-line treatment of metastatic RCC is currently VEGF TKI/ICI combination therapy or dual ICI therapy; a prognostic biomarker for determining which patients may benefit from up-front doublet ICI therapy versus TKI could transform RCC treatment and promote more personalized cancer care [53].